Newron Pharmaceuticals 2024 Investor Day on June 25, 2024, in New York City

EQS-News: Newron Pharmaceuticals S.p.A. / Key word(s): Miscellaneous
Newron Pharmaceuticals 2024 Investor Day on June 25, 2024, in New York City

18.06.2024 / 17:45 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Newron Pharmaceuticals 2024 Investor Day on June 25, 2024, in New York City

Three of the world's leading key opinion leaders (KOL) in neuroscience and
schizophrenia to review and present findings on Newron's evenamide program
for treatment-resistant schizophrenia

The company will host a Live-Webcast of the event, beginning at 9:00 AM EDT
(2:00 PM GMT, 3:00 PM CEST)

Milan, Italy and Morristown, NJ, USA - June 18, 2024 - Newron
Pharmaceuticals S.p.A. (Newron) (SIX: NWRN, XETRA: NP5), a biopharmaceutical
company focused on the development of novel therapies for patients with
diseases of the central and peripheral nervous system (CNS), today announced
that it will host its 2024 Investor Day on Tuesday, June 25, 2024, at
Convene, 530 Fifth Avenue (between 44th and 45th Streets) in New York City,
from 9:00-11:00 AM EDT.

This comprehensive research and investor update event will focus on Newron's
clinical, scientific and commercial plans for evenamide for chronic and
treatment-resistant schizophrenia.

Three of the leading KOLs in neuroscience and schizophrenia will review
Newron's Phase III evenamide program and explore the unmet needs, new
concepts and recent neurobiological findings for treating poor responders
and patients with treatment-resistant schizophrenia (TRS).

These leading experts in psychiatry and schizophrenia are:

Anthony Grace, Ph.D., is Editor-in-Chief, International Journal of
Neuropsychopharmacology, Distinguished Professor of Neuroscience, and
Professor of Psychiatry and Psychology at the University of Pittsburgh. Dr.
Grace will present breakthrough pre-clinical data on treatment-resistant
schizophrenia:

Evenamide can exert unique efficacy in schizophrenia by targeting the site
of pathology: preclinical evidence supports effects seen in patients with
TRS

John Kane, M.D., Co-Director & Professor, Institute of Behavioural Science,

Feinstein Institutes for Medical Research, and Professor of Psychiatry,
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. One of
the leading researchers in the field of schizophrenia, Dr. Kane will address
the topic:

Difficult to treat, poorly responding patients with schizophrenia; new,
unique results with evenamide offer new hope for these patients

Stephen R. Marder, M.D., Daniel X. Freedman Professor of Psychiatry at the
Semel Institute of Neuroscience & Human Behavior at UCLA and the Director of
the Section on Psychosis at the UCLA Neuropsychiatric Institute. Dr.
Marder's research has focused on the treatment of schizophrenia and the
pharmacology of antipsychotic drugs and he will present: New Hope for
Patients with Treatment-Resistant Schizophrenia; Unique Results with
Evenamide, a Glutamate Modulator, as an Add-On Medication

Stefan Weber, Chief Executive Officer and Ravi Anand, M.D., Chief Medical
Officer of Newron will host the event, and will also present updates on
evenamide's clinical and registration program.

The event will be held at Convene, 530 Fifth Avenue (between 44th and 45th
Streets) in New York City, from 9:00 - 11:00 AM EDT. Institutional
investors, business partners, analysts and media representatives who are
interested in attending in person, or virtually, must pre-register here
(https://event.webcasts.com/starthere.jsp?ei=1674805&tp_key=06b6bdbd3e).
For any additional information, please email newron@lavoiehealthscience.com.

International telephone access to the Investor Day conference is also
available at the following numbers:

Switzerland/Europe: +41 (0)800 835 525

United Kingdom: +44 (0)800 756 3429

Japan: +81 00 531 161 384

United States: +1 (877) 407 8029

To ensure a timely connection, users are recommended to dial in at least 10
minutes prior to the scheduled conference. The webcast will be archived on
the Company's website for one month after the date of the event.

About evenamide

Evenamide, an orally available new chemical entity, specifically blocks
voltage-gated sodium channels (VGSCs) and is devoid of biological activity
at >130 other CNS targets. It normalizes glutamate release induced by
aberrant sodium channel activity (veratridine-stimulated), without affecting
basal glutamate levels, due to inhibition of VGSCs. Combinations of
ineffective doses of evenamide and other APs, including clozapine, were
associated with benefit in animal models of psychosis, suggesting synergies
in mechanisms that may provide benefit in patients who are poor responders
to current APs, including clozapine.

About Newron Pharmaceuticals

Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on the
development of novel therapies for patients with diseases of the central and
peripheral nervous system. The Company is headquartered in Bresso near
Milan, Italy. Xadago®/safinamide has received marketing authorization for
the treatment of Parkinson's disease in the European Union, Switzerland, the
UK, the USA, Australia, Canada, Latin America, Israel, the United Arab
Emirates, Japan and South Korea, and is commercialized by Newron's Partner
Zambon. Supernus Pharmaceuticals holds the commercialization rights in the
USA. Meiji Seika has the rights to develop and commercialize the compound in
Japan and other key Asian territories. Newron is also developing evenamide
as the potential first add-on therapy for the treatment of patients with
symptoms of schizophrenia. For more information, please visit:
www.newron.com

For more information, please contact:

Newron
Stefan Weber
CEO
+39 02 6103 46 26
pr@newron.com

UK/Europe
Simon Conway / Ciara Martin / Natalie Garland-Collins
FTI Consulting
+44 20 3727 1000
SCnewron@fticonsulting.com

Switzerland
Valentin Handschin
IRF
+41 43 244 81 54
handschin@irf-reputation.ch

Germany/Europe
Anne Hennecke / Caroline Bergmann
MC Services
+49 211 52925222
newron@mc-services.eu

USA
Paul Sagan
LaVoieHealthScience
+1 617 374 8800, Ext. 112
psagan@lavoiehealthscience.com

Important Notices

This document contains forward-looking statements, including (without
limitation) about (1) Newron's ability to develop and expand its business,
successfully complete development of its current product candidates, the
timing of commencement of various clinical trials and receipt of data and
current and future collaborations for the development and commercialization
of its product candidates, (2) the market for drugs to treat CNS diseases
and pain conditions, (3) Newron's financial resources, and (4) assumptions
underlying any such statements. In some cases, these statements and
assumptions can be identified by the fact that they use words such as
"will", "anticipate", "estimate", "expect", "project", "intend", "plan",
"believe", "target", and other words and terms of similar meaning. All
statements, other than historical facts, contained herein regarding Newron's
strategy, goals, plans, future financial position, projected revenues and
costs and prospects are forward-looking statements. By their very nature,
such statements and assumptions involve inherent risks and uncertainties,
both general and specific, and risks exist that predictions, forecasts,
projections and other outcomes described, assumed or implied therein will
not be achieved. Future events and actual results could differ materially
from those set out in, contemplated by or underlying the forward-looking
statements due to a number of important factors. These factors include
(without limitation) (1) uncertainties in the discovery, development or
marketing of products, including without limitation difficulties in
enrolling clinical trials, negative results of clinical trials or research
projects or unexpected side effects, (2) delay or inability in obtaining
regulatory approvals or bringing products to market, (3) future market
acceptance of products, (4) loss of or inability to obtain adequate
protection for intellectual property rights, (5) inability to raise
additional funds, (6) success of existing and entry into future
collaborations and licensing agreements, (7) litigation, (8) loss of key
executive or other employees, (9) adverse publicity and news coverage, and
(10) competition, regulatory, legislative and judicial developments or
changes in market and/or overall economic conditions. Newron may not
actually achieve the plans, intentions or expectations disclosed in
forward-looking statements and assumptions underlying any such statements
may prove wrong. Investors should therefore not place undue reliance on
them. There can be no assurance that actual results of Newron's research
programs, development activities, commercialization plans, collaborations
and operations will not differ materially from the expectations set out in
such forward-looking statements or underlying assumptions. Newron does not
undertake any obligation to publicly update or revise forward-looking
statements except as may be required by applicable regulations of the SIX
Swiss Exchange or the Dusseldorf Stock Exchange where the shares of Newron
are listed. This document does not contain or constitute an offer or
invitation to purchase or subscribe for any securities of Newron and no part
of it shall form the basis of or be relied upon in connection with any
contract or commitment whatsoever.


---------------------------------------------------------------------------

18.06.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        Newron Pharmaceuticals S.p.A.
                   via Antonio Meucci 3
                   20091 Bresso
                   Italy
   Phone:          +39 02 610 3461
   Fax:            +39 02 610 34654
   E-mail:         pr@newron.com
   Internet:       www.newron.com
   ISIN:           IT0004147952
   WKN:            A0LF18
   Listed:         Regulated Unofficial Market in Dusseldorf
                   (Primärmarkt); London, SIX
   EQS News ID:    1928025

End of News EQS News Service
---------------------------------------------------------------------------

1928025 18.06.2024 CET/CEST